Sector News

Seattle Genetics on a ‘great trajectory,’ looks to grow staff by 100

April 24, 2015
Life sciences
Seattle Genetics is hiring for 100 positions, Chief Operating Officer Eric Dobmeier said Thursday.
 
The Bothell-based biotech company (Nasdaq: SGEN) is looking to fill positions ranging from biostatisticians and research associates to the head of its cancer research program and vice president of marketing.
 
That growth is to keep the company, which develops cancer treatments, on track with what a Seattle Genetics spokeswoman called a “great trajectory.”
 
Hiring new people will also coincide with the company ramping up spending in coming years to support preclinical developments, clinical trial activities and continue the commercialization of its flagship product Adcetris, according to a recent filing with the Securities and Exchange Commission. Adcetris is used to treat lymphoma.
 
Seattle Genetics is also investing heavily in its pipeline. That was one factor that led to a $27 million loss in the fourth quarter last year.
 
Even after that loss, though, the company’s stock held steady. Today it is trading at about $37 per share.
 
The company will report first quarter earnings next week.
 
By Annie Zak
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach